AVP-786

AVP-786 is an investigational small molecule combination therapy consisting of deudextromethorphan hydrobromide (a deuterated form of dextromethorphan) and quinidine sulfate. It is designed as a second-generation successor to Nuedexta (AVP-923). Deudextromethorphan acts as a sigma-1 receptor agonist and an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, while quinidine serves as a potent inhibitor of the CYP2D6 enzyme to increase the systemic exposure of the dextromethorphan component. The drug was primarily developed by Avanir Pharmaceuticals (acquired by Otsuka) in collaboration with Concert Pharmaceuticals. It has been evaluated for several neuropsychiatric conditions, including agitation in Alzheimer's disease, schizophrenia, and Intermittent Explosive Disorder (IED). However, the Phase 2 trial for IED was terminated due to recruitment difficulties, and the Phase 3 program for Alzheimer's agitation was discontinued in 2024 after failing to meet primary endpoints.

Other names

Deudextromethorphan hydrobromide + quinidine sulfated6-DM/QDeudextromethorphan + quinidine